The case of a 56-year-old woman who developed neurosarcoidosis and was discovered to have inferior vena cava and lower extremity thromboses is described. She was found to have anticardiolipin antibodies. This newly described association of antiphospholipid antibody syndrome with sarcoidosis is discussed and the relevant literature reviewed.
Introduction
The association of sarcoidosis with the antiphospholipid antibody syndrome is not well defined. A review of the literature suggests that about 38% of patients with sarcoidosis have antiphospholipid antibodies, but clinical manifestations of the antiphospholipid antibody syndrome are rare. 1 The report of a case of well-documented sarcoidosis with multiple, deep venous thromboses and elevated antiphospholipid antibodies follows.
Case history
A 56-year-old white female developed diarrhea, fever, weight loss and night sweats. A colonoscopy showed granular, erythematous mucosa. Biopsies showed crypt abscesses and two epithelioid granulomata. She was diagnosed with inflammatory bowel disease. Her symptoms slowly resolved with therapy, but intermittent abdominal pain persisted. At 1 month later a routine mammogram showed bilateral axillary lymphadenopathy, up to 3 cm in size. A computed tomography (CT) scan of the abdomen and pelvis revealed adenopathy of the para-aortic and external iliac chains, with the largest nodes measuring 2 cm in diameter. A month later she underwent biopsy of an axillary lymph node, which revealed extensive granulomatous inflammation. Cytology of a CT-guided biopsy of a periaortic lymph node showed a normal lymphocyte population and no malignant cells. Stains and cultures for fungi and acid fast bacilli were negative as were fungal serologies. Over the next 3 months she developed back and bilateral lower extremity pain, as well as weakness and loss of sensation in the legs. She also noted loss of appetite and a 40 pound weight loss. She denied any personal or family history of blood clots or miscarriages. She presented to the authors' hospital when her neurological symptoms became acutely worse over the course of a few days.
A physical examination demonstrated extensive lymphadenopathy involving the submandibular, posterior cervical, supraclavicular, axillary and inguinal regions. On neurological examination she had weakness of all leg muscles; decreased pinprick, light touch and vibratory sense to the midcalf level in a glove and stocking distribution; diminished patellar tendon reflexes and absent ankle reflexes; and no proprioception in her toes. She had an abnormal Romberg and a wide based gait.
A lumbar puncture showed 11 white blood cells with a predominance of lymphocytes. All other CSF tests, including cytology and cultures, were negative. A chest X-ray was normal. CT scans of the chest, abdomen and pelvis showed extensive adenopathy of the axillary, internal mammary, subcarinal, pretracheal, preaortic, anterior mediastinal, periaortic, aortocaval, retrocrural, retroperitoneal, mesenteric and obturator lymph nodes. There was a question of an inferior vena cava thrombus without evidence of extrinsic compression of the vein. A subsequent venogram showed a thrombus in the inferior vena cava, proximal to the iliac confluence. Ultrasound studies of the lower extremities showed extensive thrombosis involving the left popliteal, posterior tibial and peroneal veins.
Laboratory studies showed an erythrocyte sedimentation rate of 47 mm/h (0-30) and angiotensin converting enzyme of 348 U/l ). An RPR was non-reactive. The IgG anticardiolipin antibody was 19 GPL (0-10), IgA was 20 APL (0-10) and IgM was 7 MPL (0-10). A hypercoagulable profile was normal including antithrombin III, protein C, protein S, plasminogen function, homocysteine and activated protein C. Ophthalmologic examination showed bilateral choroiditis. Pulmonary function tests were normal except for diminished diffusion capacity. A sural nerve biopsy showed non-caseating granulomas and vasculitis. Granulomas were also confirmed on review of the axillary lymph node and colonic biopsies previously carried out at other institutions.
The patient was started on prednisone 3 days after presentation and within 2 days the back pain, numbness and paresthesias had improved together with her appetite and strength. She was anticoagulated initially with intravenous heparin, and then was maintained on oral warfarin. Weekly oral methotrexate was added to her regimen. After 9 months of anticoagulation, warfarin therapy was discontinued. At 1 year she remained on the same dose of metho-trexate and 5 mg of prednisone every other day. She was essentially back to her baseline and had returned to work full-time. Only mild sensory deficits remained in both distal feet with persistent loss of ankle reflexes. A repeat duplex ultrasound of the lower extremities demonstrated remote thrombosis in the left popliteal and posterior tibial veins. Anticardiolipin antibody levels were within the normal range.
Discussion
The lupus anticoagulant was originally described in lupus patients who manifested no hemorrhagic problems. The term 'lupus anticoagulant' is a misnomer because subsequent studies have showed a link between lupus anticoagulant and the occurrence of thrombosis. Further investigations have shown this factor to be comprised of antibodies directed against anionic phospholipids, which have been termed antiphospholipid antibodies. Presently there are several antiphospholipid antibodies that have been classified by their specificity for phospholipid epitopes. One of these, the anticardiolipin antibody, has been well studied in various disease entities, 2 and up to 30% of patients with anticardiolipin antibody will ultimately develop clinical evidence of thrombosis.
The antiphospholipid antibody syndrome is defined as the presence of anticardiolipin antibody with associated thrombosis, thrombocytopenia, fetal loss or neurological syndromes in the absence of confounding factors. 3 The mechanism of thrombosis associated with anticardiolipin antibody is poorly understood. Anticardiolipin antibodies may damage vascular endothelial cells, limiting the production of endothelium-derived relaxing factor, or binding to phospholipids in the cell walls and thus inhibiting prostacyclin synthesis, rendering the vessels susceptible to spasm and ischemic damage. In vitro studies have shown platelet activation and protein C inhibition in patients with this syndrome, although this has not been supported by in vivo studies. 4 Sarcoidosis has not been previously associated with the antiphospholipid antibody syndrome. A patient with sarcoidosis and anticardiolipin antibodies was reported to have multi-infarct dementia in one series, 5 but it is unclear how the diagnosis of sarcoidosis was made; the patient was 71 years old, thus potentially confounding the issue with regard to the etiology of his ischemic disease. A Japanese study examined the presence of antiphospholipid antibodies in 55 patients with sarcoidosis. 1 A total of 21 (38%) patients had IgG or IgM antibodies compared with five of 70 (7%) control patients. There was no correlation between the presence of antiphospholipid antibodies and disease activity, but a significant correlation with the presence of extrapulmonary disease was observed. There was no evidence of a hypercoagulable state in this series. In another series of patients with uveitis, none of nine patients with sarcoidosis had anticardiolipin antibodies. 6 The patient in this report had neurosarcoidosis with ocular involvement, diffuse lymphadenopathy, subclinical pulmonary disease and probable gastrointestinal disease, a rare but recognized manifestation of sarcoidosis. She also had extensive thrombosis involving the inferior vena cava and left lower extremity veins and none of the usual risk factors Vascular Medicine 1999; 4: 37-39 for thrombosis. She was found to have anticardiolipin antibodies and thus meets the definition for antiphospholipid antibody syndrome. It is possible that such antibodies may exist in individuals with sarcoidosis without any relationship to the thrombotic manifestations of this syndrome.
In order to assess that possibility further, a review of the literature was carried out to investigate a potential association between sarcoidosis and thrombotic events. A few case reports describe patients with presumed or definite sarcoidosis with thrombosis of the portal vein, 7 dural sinus, 8, 9 renal vein in a patient with nephrotic syndrome, 10 and retinal veins, 11 as well as intracardiac thrombi, 12, 13 and a lower extremity thrombus in a patient on oral contraceptives. 14 Some of these patients have alternative explanations for the thrombotic event, and most had adjacent inflammatory foci. None of these patients had levels of antiphospholipid antibodies measured. In the patient in this report, the distribution of the thrombi was more typical, 15 no alternative explanation for the thrombi could be found and they did not seem to be secondary to an adjacent focus of inflammation, thus supporting the hypothesis of a true cause-andeffect relationship between the presence of the antiphospholipid antibodies and the thrombotic complications.
Exposure to an unknown antigen is thought to lead to an exaggerated cellular immune response in target tissues of patients with sarcoidosis. On the other hand, the antiphospholipid antibody syndrome seems to be mediated by an autoimmune antibody response. It is tempting to speculate that a common antigenic stimulus led to both disease processes. Further study of the role of antiphospholipid antibodies in patients with sarcoidosis may help elucidate the etiology of this challenging disease.
